{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:32:14Z","timestamp":1786368734095,"version":"build-2736575974"},"reference-count":27,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"unspecified","delay-in-days":298,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ASHE"],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S2732494X24004455_as1\">\n\t    <jats:title>Objective:<\/jats:title>\n\t    <jats:p>We sought to compare patient outcomes between carbapenem-resistant <jats:italic>Enterobacterales<\/jats:italic> (CRE) and carbapenem-susceptible <jats:italic>Enterobacterales<\/jats:italic> (CSE) infections at our academic medical center.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X24004455_as2\">\n\t    <jats:title>Design:<\/jats:title>\n\t    <jats:p>We conducted a retrospective cohort study of adult patients with a positive culture of E. coli, E. cloacae, K. aerogenes, K. oxytoca, and\/or K. pneumoniae admitted at UK HealthCare (January 1, 2010\u2013December 31, 2019). Based on the type of pathogen on the date of the first culture (index date), patients were included in the CRE (i.e., exposed) group, or the CSE (comparator) group. Exclusion criteria were age &lt; 18 years old, pregnancy, endocarditis, osteomyelitis, necrotizing fasciitis, or cystic fibrosis. We evaluated the impact of CRE vs CSE on a composite outcome of 30-day of all-cause mortality or discharge to hospice using Kaplan\u2013Meier survival curves and Cox proportional hazard regression with inverse probability of treatment weights (IPTW).<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X24004455_as3\">\n\t    <jats:title>Results:<\/jats:title>\n\t    <jats:p>Of 17,839 hospitalized patients, 128 and 6,953 patients were included in the CRE and CSE groups, respectively. Baseline differences existed in sex-assigned-at-birth, admission source, time-to-index culture, and infection type\/severity. Most CRE index cultures observed (76%) only exhibited resistance to ertapenem. IPTW-adjusted HR [95% CI] of composite outcome was 0.99 [0.65, 1.51] after 30 days. Follow-up analysis in patients with carbapenem-non-susceptible <jats:italic>Enterobacterales<\/jats:italic>bloodstream infections on index yielded an HR of 1.38 [0.85, 2.24].<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X24004455_as4\">\n\t    <jats:title>Conclusions:<\/jats:title>\n\t    <jats:p>Risk of composite outcome was not estimated to differ between patients with CRE and CSE in the overall analysis. Although follow-up analysis identified an increased risk, we cannot statistically distinguish this from a null effect.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/ash.2024.445","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T11:12:22Z","timestamp":1729854742000},"source":"Crossref","is-referenced-by-count":1,"title":["The effect of carbapenem-resistant versus carbapenem-susceptible <i>Enterobacterales<\/i> infections on patient outcomes at an academic medical center"],"prefix":"10.1017","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-5350","authenticated-orcid":false,"given":"Justin A.","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0367-7135","authenticated-orcid":false,"given":"David S.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela C.","family":"Moga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"S2732494X24004455_ref16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis588"},{"key":"S2732494X24004455_ref20","unstructured":"20. Centers for Disease Control and Prevention. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 Update - CRE Toolkit. 2015. Available at: https:\/\/www.cdc.gov\/hai\/pdfs\/cre\/CRE-guidance-508.pdf. Accessed October 3, 2023."},{"key":"S2732494X24004455_ref21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01105-21"},{"key":"S2732494X24004455_ref27","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/155.2.176"},{"key":"S2732494X24004455_ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-2742-9"},{"key":"S2732494X24004455_ref7","volume-title":"CLSI Supplement M100","year":"2020"},{"key":"S2732494X24004455_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0"},{"key":"S2732494X24004455_ref12","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181c1ea43"},{"key":"S2732494X24004455_ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054971"},{"key":"S2732494X24004455_ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00671.x"},{"key":"S2732494X24004455_ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab643"},{"key":"S2732494X24004455_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30755-8"},{"key":"S2732494X24004455_ref23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa122"},{"key":"S2732494X24004455_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.10.004"},{"key":"S2732494X24004455_ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1152-0"},{"key":"S2732494X24004455_ref24","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2016.1106940"},{"key":"S2732494X24004455_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2019.03.020"},{"key":"S2732494X24004455_ref3","unstructured":"3. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Available at: https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Accessed May 1, 2020."},{"key":"S2732494X24004455_ref8","first-page":"188","article-title":"Charlson comorbidity index: ICD-9 update and ICD-10 translation","volume":"12","author":"Glasheen","year":"2019","journal-title":"Am Heal Drug Benefits"},{"key":"S2732494X24004455_ref15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02166-13"},{"key":"S2732494X24004455_ref9","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"S2732494X24004455_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz194"},{"key":"S2732494X24004455_ref1","volume-title":"Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis","year":"2017"},{"key":"S2732494X24004455_ref18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw741"},{"key":"S2732494X24004455_ref25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad428"},{"key":"S2732494X24004455_ref26","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"S2732494X24004455_ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2383-z"}],"container-title":["Antimicrobial Stewardship &amp; Healthcare Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2732494X24004455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T11:12:25Z","timestamp":1729854745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2732494X24004455\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"alternative-id":["S2732494X24004455"],"URL":"https:\/\/doi.org\/10.1017\/ash.2024.445","relation":{},"ISSN":["2732-494X"],"issn-type":[{"value":"2732-494X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e189"}}